Physician profile
John C Vassallo
NPI 1275590119
$7,250.76
in general payments reported to CMS, 2019-2025
59 companies · $953 in 2025
The $953 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $746 · 2021: $1,021 · 2022: $1,278 · 2023: $1,355 · 2024: $1,083 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.88 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,547.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Vanda Pharmaceuticals INC. | $384.73 | 2020-2024 | Fanapt |
| Novo Nordisk INC | $370.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.68 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $321.17 | 2019-2025 | |
| Abbvie INC. | $319.61 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $287.07 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $270.92 | 2019-2025 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $229.53 | 2019-2024 | |
| Pfizer INC. | $224.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.40 | 2022-2025 | |
| Glaxosmithkline, LLC. | $203.62 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $183.36 | 2019-2025 | Xarelto, Spravato |
| Sunovion Pharmaceuticals INC. | $138.58 | 2019-2022 | |
| Amarin Pharma, INC. | $129.82 | 2019-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $100.67 | 2019-2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $97.06 | 2022-2023 | Quviviq |
| Lexicon Pharmaceuticals, INC. | $93.60 | 2023-2024 | Inpefa |
| Nestle Healthcare Nutrition INC. | $91.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $85.07 | 2019-2022 | |
| Ucb, INC. | $84.38 | 2023-2025 | Nayzilam, Briviact |
| Biogen, INC. | $79.79 | 2021-2022 | |
| Dexcom, INC. | $79.75 | 2022-2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $77.66 | 2023 | Vivitrol |
| Abbott Laboratories | $77.64 | 2022-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $74.81 | 2022-2023 | Eliquis |
| Exact Sciences Corporation | $73.09 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $70.93 | 2023-2025 | Aptiom, Gemtesa |
| Otsuka America Pharmaceutical, INC. | $68.73 | 2023-2025 | Rexulti, Abilify Maintena |
| Scpharmaceuticals INC. | $67.97 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $65.92 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $64.92 | 2019-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.50 | 2024-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $58.27 | 2024-2025 | Xtampza |
| Aimmune Therapeutics, INC. | $47.48 | 2025 | Zenpep, Vowst |
| Neurelis, INC. | $44.06 | 2022-2023 | Valtoco |
| Nevro Corp. | $40.32 | 2024 | Senza |
| Lundbeck LLC | $38.71 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $37.42 | 2022-2023 | Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $36.91 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $29.39 | 2022 | |
| Axsome Therapeutics, INC. | $26.29 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $24.69 | 2021 | |
| Eisai INC. | $24.33 | 2021 | |
| Radius Health, INC. | $23.50 | 2020-2021 | |
| Acorda Therapeutics, INC | $21.49 | 2020 | |
| Sanofi Pasteur INC. | $18.68 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.83 | 2025 | Nuzyra |
| Abiomed | $17.65 | 2024 | Impella |
| Corium, LLC | $16.56 | 2023 | Azstarys |
| Esperion Therapeutics, INC. | $16.28 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.09 | 2022 | |
| Ardelyx, INC. | $15.90 | 2024 | Ibsrela |
| Urovant Sciences INC | $15.86 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $13.90 | 2024 | Rhythm Express |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2022 | |
| Allergan, INC. | $12.13 | 2020 | |
| Ibsa Pharma INC. | $10.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vassallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.